In four classes, and even if the percentage of patients with AGAs in IBC did not remain significantly superior (classes of HER/EGFR inhibitors, of other tyrosine kinase receptors inhibitors, and of CDK4/6 inhibitors) or inferior (class of PI3K/AKT/mTOR inhibitors) to that of patients with AGAS in non-IBC in multivariate analysis, the percentages were high in IBC patients. The gene discussed is MTOR; the disease is inflammatory breast carcinoma.